FDA officials said the questions about accelerated approval of PD-1 and PD-L1 drugs have been largely resolved, thanks in part to guidance from the Oncologic Drugs Advisory Committee.
Spanning part of September and October, it is a time to celebrate and recognize Hispanics or Latinos or Latinx persons* for their contributions. This nationwide observation begins on Sept. 15 when several countries in Latin America celebrate independence—Costa Rica, El Salvador, Guatemala, Honduras, and Nicaragua. Mexico celebrates independence on Sept. 16 and Chile on Sept. 18. Towards the end of Hispanic Heritage Month, Oct. 12 is also recognized as Día de la Raza.1 Persons of Hispanic ancestry have walked the Americas since 1492.
Joseph R. Bertino, a physician who made fundamental discoveries in cancer biology, defined curative cancer treatment regimens, trained generations of influential cancer researchers, ran productive laboratories, and served as the inaugural director of Yale Cancer Center, died on Oct. 10. He was 91.
My dear friend and mentor, Joseph R. Bertino, MD, died Sunday, Oct. 10, 2021, in New Brunswick, NJ, after an extended illness.
Congress needs to increase the FY22 base budgets of NIH and NCI by $3.2 billion and $1.1 billion, respectively, over FY21 levels, the American Association for Cancer Research said in its 2021 Cancer Progress Report.
Before Janet Rowley, few scientists suspected that chromosomal aberrations caused cancer. Beginning in the 1970s, however, she made a series of fundamental discoveries demonstrating that specific chromosomal changes caused certain types of leukemia.
An argument can be made that only a government research agency like NCI has the capacity to answer questions about monitoring pancreatic cysts—and how some of them turn malignant.
Prevention and early detection trials have been especially vulnerable to being disrupted by the COVID-19 lockdown, and a comparison of two regimens for monitoring pancreatic cysts—EA2185—was more vulnerable than most.
Prevention and early detection studies frequently require engaging physicians from specialties other than oncologists, said Peter O’Dwyer and Mitchell Schnall, co-chairs of ECOG-ACRIN Cancer Research Group.
Vinay Prasad might well have made his contrarian points without invoking the specter of the Third Reich. He didn’t have to go there—but he did. Voluntarily.
